Navigation Links
Bernstein Liebhard LLP Launches New GranuFlo Lawsuit Website for Individuals Allegedly Injured by Recalled Dialysis Medications
Date:12/8/2013

New York, New York (PRWEB) December 08, 2013

The attorneys at Bernstein Liebhard LLP have launched a new website for individuals seeking to file NaturaLyte and GranuFlo lawsuit (http://www.dialysislawsuitclaims.com/) claims. Vital to anyone who may have suffered a stroke, heart attack, sudden cardiac death or another cardiovascular injury allegedly stemming from either of these dialysis medications, information about last year’s GranuFlo recall will be included on the Firm’s new website.

Individuals who are eligible to file a lawsuit against Fresenius Medical Care, the manufacturer of these acid concentrates, may have experienced heart problems within 72 hours of a dialysis treatment that used GranuFlo or NaturaLyte. According to court documents filed in November, almost 400 cases alleging injuries caused by these medications are now pending in a federal litigation underway in the U.S. District Court, District of Massachusetts. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)

“With this new website, individuals who may have been injured as a result of GranuFlo or NaturaLyte will be connected with the resources they need to file a claim against Fresenius,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs including GranuFlo and NaturaLyte. The Firm is currently offering free and confidential case evaluations to anyone who may have sustained the life-threatening heart problems associated with either of these medications.

GranuFlo Lawsuits
A recent update from the U.S. Judicial Panel on Multidistrict Litigation (JPML) indicates that 393 NaturaLyte and GranuFlo lawsuits were pending in the federal Massachusetts proceeding as of November 18th, 2013. Cases filed in this litigation, which held its most recent status conference on November 1, 2013, were brought on behalf of individuals who received either of the acid concentrates during dialysis treatments and who are alleged to have suffered a stroke, heart attack, sudden cardiac death, or another heart-related injury.

The U.S. Food and Drug Administration (FDA) issued a Class I recall for GranuFlo and NaturaLyte in June 2012 after the federal agency found that the acid concentrates may put a patient at risk for serious injury and death. This announcement followed an Urgent Product Notification from Fresenius in March 2012 that alerted the general public of GranuFlo and NaturaLyte’s association with sudden cardiac death, heart attacks, cardiopulmonary arrest, strokes and other injuries.

According to a New York Times report published shortly after the GranuFlo recall, the FDA’s involvement with the Fresenius medications did not end there. After becoming aware of an internal memo sent in November 2011 to physicians operating in the company’s own dialysis clinics, the federal agency began to investigate whether the dialysis drug supplier violated federal regulations in its handling of the recall. According to the memo, more than 900 deaths had occurred in patients who underwent dialysis treatments aided by GranuFlo and NaturaLyte. Fresenius did not alert doctors in facilities outside its network of these fatalities at the time. *

Dialysis lawsuits filed in U.S. federal and state courts now allege that the manufacturer failed to adequately warn doctors and patients about its products’ risk for these side effects, which may be caused by the acid concentrates’ potential to cause elevated levels of bicarbonate in the bloodstream. In turn, this may result in a condition referred to as metabolic alkalosis.

In addition to claims pending in the federal proceeding, court documents show several GranuFlo and NaturaLyte lawsuits pending in Massachusetts’ Middlesex County Superior Court. (In re: Consolidated Fresenius Cases, No. MICV2013-03400-O)

Dialysis patients who may have suffered cardiovascular side effects within 72 hours of receiving GranuFlo or NaturaLyte may be eligible to file a lawsuit against Fresenius Medical Care. Learn More about the GranuFlo recall by visiting Bernstein Liebhard LLP’s new website, or by speaking with one of the Firm’s lawyers directly. To arrange for a free case review, please call 800-511-5092.

*nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this
advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
###

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.dialysislawsuitclaims.com/
https://plus.google.com/115936073311125306742?rel=author

Read the full story at http://www.prweb.com/releases/granuflo-lawsuit/granuflo-recall/prweb11377005.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes New Plaintiff Filing in Federal Ethicon Vaginal Mesh Litigation
2. DePuy ASR Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal DePuy ASR Hip Recall Litigation
3. Ethicon Transvaginal Mesh Lawsuits Mount, as Bernstein Liebhard LLP Notes More than 16,000 Filings in Federal, State Litigations
4. DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Order Delaying Consideration of Remand Motions in Federal Pinnacle Hip Litigation
5. As Pradaxa Lawsuits Move Forward, Bernstein Liebhard LLP Notes Manufacturer is Working on Possible Antidote for Internal Bleeding Caused by the Blood-Thinner
6. DePuy Pinnacle Lawsuit Claims Mount, as Bernstein Liebhard LLP Notes Nearly 6,000 Filings in Federal Pinnacle Hip Litigation
7. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Johnson & Johnson Bid to Keep Clinical Studies Under Seal
8. Stryker Hip Lawsuit News: Bernstein Liebhard LLP Notes Scheduling of December Case Management Conference in New Jersey Stryker Hip Recall Litigation
9. Transvaginal Mesh Lawsuits Progress, As Bernstein Liebhard LLP Notes Scheduling of Motions Hearing in Federal Vaginal Mesh Litigations
10. Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Conference in New Jersey Vaginal Mesh Litigations
11. Federal GranuFlo Lawsuits Progress, as Bernstein Liebhard LLP Notes Issuance of New Case Management Order in GranuFo Recall Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical Officer Dr. ... colleagues, skilled nursing facility medical directors and other clinicians at various events in ... , "At many of these conferences we get to educate other physicians, facility ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Oct. 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... facility in Las Piedras, Puerto Rico ... blades. Following ... facility sustained minor structural damage, temporary loss of power ... have been completed, manufacturing operations have resumed, and the ...
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
(Date:10/5/2017)... 5, 2017  In response to the nationwide ... Maxillofacial Surgeons (AAOMS) released prescribing recommendations that urge ... used as a first-line therapy to manage a ... Recognizing the value and importance ... "Opioid Prescribing: Acute and Postoperative Pain Management" stresses ...
Breaking Medicine Technology: